Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region

Blood

Volumn 118, Issue 19, 2011, Pages 5283-5291

  Fu, Xiaoyun ^a,b   Chen, Junmei ^a   Gallagher, Ryan ^a   Zheng, Ying ^c   Chung, Dominic W ^b   López, José A ^a,b  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; METHIONINE; MYELOPEROXIDASE; OXIDIZING AGENT; RISTOCETIN; UREA; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; LIQUID CHROMATOGRAPHY; NEUTROPHIL; OXIDATION; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHEAR STRESS; TANDEM MASS SPECTROMETRY; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGLUTINATION; THROMBOSIS;

EID: 81055131933     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-331074     Document Type: Article

References (35)

1. Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2010;36(1):71-81.
2. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor-too sweet for their own good. Haemophilia. 2010;16(suppl 5):194-199.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. (Pubitemid 28411134)
4. Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood. 1987;69(5):1531-1534. (Pubitemid 17085319)
5. Johnsen J, López JA. VWF secretion: what's in a name? Blood. 2008;112(4):926-927.
6. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971-3977. (Pubitemid 35332036)
7. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006;57: 419-436.
8. Groot E, de Groot PG, Fijnheer R, Lenting PJ. The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol. 2007;14(3):284-289. (Pubitemid 46597616)
9. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004; 170(7):766-772. (Pubitemid 39298992)
10. Bridges DJ, Bunn J, Van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood. 2010;115(7): 1472-1474.
11. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115(3):706-712.
12. Hulstein JJ, de Groot PG, Silence K, et al. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106(9):3035-3042. (Pubitemid 41565896)
13. Chen J, Reheman A, Gushiken FC, et al. Nacetylcysteine reduces the size and activity of von Willebrand factor: a potential therapy for thrombotic thrombocytopenic purpura. J Clin Invest. 2011;121(2):593-603.
14. Gerstein M. A resolution-sensitive procedure for comparing protein surfaces and its application to the comparison of antigen-combining sites. Acta Cryst. 1992;A48:271-276.
15. Shrake A, Rupley JA. Environment and exposure to solvent of protein atoms. Lysozyme and insulin. J Mol Biol. 1973;79(2):351-371.
16. Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. J Mol Biol. 1971;55(3):379-400.
17. Shankaran H, Neelamegham S. Hydrodynamic forces applied on intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J. 2004;86(1 pt 1):576-588. (Pubitemid 38067487)
18. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-2950. (Pubitemid 26357374)
19. Singh I, Themistou E, Porcar L, Neelamegham S. Fluid shear induces conformation change in human blood protein von Willebrand factor in solution. Biophys J. 2009;96(6):2313-2320.
20. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U SA. 2007;104(19):7899-7903. (Pubitemid 47185848)
21. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330-1334.
22. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998;273(17): 10396-10401. (Pubitemid 28227648)
23. Zhang Q, Zhou YF, Zhang CZ, et al. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A. 2009;106(23): 9226-9231.
24. Bienkowska J, Cruz M, Atiemo A, Handin R, Liddington R. The von willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif. J Biol Chem. 1997;272(40): 25162-25167. (Pubitemid 27415701)
25. López JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol. 2004;41(1):15-23. (Pubitemid 38057781)
26. Baldauf C, Schneppenheim R, Stacklies W, et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J Thromb Haemost. 2009;7(12):2096-2105.
27. Sing CE, exander-Katz A. Elongational flow induces the unfolding of von Willebrand factor at physiological flow rates. Biophys J. 2010;98(9): L35-L37.
28. Kayal S, Jais JP, Aguini N, Chaudiere J, Labrousse J. Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med. 1998;157(3 pt 1): 776-784.
29. Baldus S, Eiserich JP, Mani A, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001;108(12):1759-1770. (Pubitemid 34015121)
30. Pendyala S, Usatyuk PV, Gorshkova IA, Garcia JG, Natarajan V. Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid Redox Signal. 2009;11(4):841-860.
31. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U SA. 2001;98(26):15215-15220. (Pubitemid 34013994)
32. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002;106(15):1962-1967. (Pubitemid 35176302)
33. Jezovnik MK, Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol. 2010;29(3):226-231.
34. Boudjeltia KZ, Ollieuz S, Piagnerelli M, et al. Plasma fibrinolysis is related to the degree of organ dysfunction but not to the concentration of von Willebrand Factor in critically ill patients. Thromb J. 2009;7:10.
35. Chen J, Hobbs WE, Le J, et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011;117(13):3680-3683.